Saudi Aramco’s Wa’ed Ventures leads $10M funding for Kure Cells to expand into Saudi Arabia and boost biotech innovation in cell therapy.
Riyadh, Saudi Arabia — Wa’ed Ventures, the $500 million venture capital arm backed by Saudi Aramco, has led a $10 million funding round for Kure Cells, a US biotechnology company developing next-generation cell therapies to combat cancer.
Also Read: Saudi Aramco to Use Drone Startup to Inspect Facilities
The round also saw participation from Qomel, a Saudi healthcare firm, and NantBio, a US-based pharmaceutical company. The investment marks a significant step in advancing Saudi Arabia’s biotechnology ecosystem, aligning with the Kingdom’s broader vision to localize life sciences and precision medicine.
Kure Cells specializes in reprogramming a patient’s immune cells to identify and destroy cancer cells. With this new funding, the company plans to expand into Saudi Arabia, establishing R&D and manufacturing facilities dedicated to accelerating cell therapy innovation.
According to Coherent Market Insights, the global cell therapy market is projected to exceed $100 billion by 2030, fueled by rapid advancements in oncology and regenerative medicine.
Kure’s planned entry into the Saudi market includes collaboration with local researchers and clinicians to align its platform with national regulatory and clinical frameworks — paving the way for new biotech synergies between the US and Saudi Arabia.
“Partnering with Kure Cells is a crucial step in localizing biotech companies in the Kingdom,” said Anas Algahtani, Acting CEO of Wa’ed Ventures. “Their rapid cell therapy manufacturing platform compresses timelines, lowers costs, and broadens patient access.”
Established in 2013, Wa’ed Ventures manages a portfolio of over 90 startups across diverse sectors, driving innovation and supporting the Kingdom’s transition to a knowledge-based economy.
